UA109109C2 - Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти) - Google Patents

Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)

Info

Publication number
UA109109C2
UA109109C2 UAA201109971A UAA201109971A UA109109C2 UA 109109 C2 UA109109 C2 UA 109109C2 UA A201109971 A UAA201109971 A UA A201109971A UA A201109971 A UAA201109971 A UA A201109971A UA 109109 C2 UA109109 C2 UA 109109C2
Authority
UA
Ukraine
Prior art keywords
variants
free base
cancer
treatment
pharmaceutical composition
Prior art date
Application number
UAA201109971A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Лоран Д. Курвуазьє
Марк Еддлстоун
Кертіс Р. Холтіванджер
Роберт Е. Маккін
Original Assignee
Сефалон, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA109109(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сефалон, Інк. filed Critical Сефалон, Інк.
Publication of UA109109C2 publication Critical patent/UA109109C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
UAA201109971A 2009-01-15 2010-01-14 Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти) UA109109C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (1)

Publication Number Publication Date
UA109109C2 true UA109109C2 (uk) 2015-07-27

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201109971A UA109109C2 (uk) 2009-01-15 2010-01-14 Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)

Country Status (16)

Country Link
US (1) US8076366B2 (cg-RX-API-DMAC7.html)
EP (1) EP2387400A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012515210A (cg-RX-API-DMAC7.html)
KR (1) KR20110110293A (cg-RX-API-DMAC7.html)
CN (2) CN102281877B (cg-RX-API-DMAC7.html)
AU (2) AU2010204765A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1004922A2 (cg-RX-API-DMAC7.html)
CA (1) CA2749101A1 (cg-RX-API-DMAC7.html)
EA (1) EA020767B1 (cg-RX-API-DMAC7.html)
IL (1) IL213725A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011007557A (cg-RX-API-DMAC7.html)
NZ (1) NZ594010A (cg-RX-API-DMAC7.html)
SG (1) SG172810A1 (cg-RX-API-DMAC7.html)
UA (1) UA109109C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010083276A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105099B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376394B2 (en) * 2009-12-23 2016-06-28 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
EP3895694A1 (en) 2010-01-28 2021-10-20 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2012176214A2 (en) * 2011-06-20 2012-12-27 Hetero Research Foundation Process for bendamustine hydrochloride
RS58744B1 (sr) 2012-03-20 2019-06-28 Eagle Pharmaceuticals Inc Tečna kompozicija za upotrebu u postupku lečenja stanja koja reaguju na bendamustin kod pacijenata kojima su potrebne smanjene zapremine za davanje
DK2827862T3 (da) 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
MX362032B (es) 2013-03-12 2019-01-04 Cephalon Inc Formulaciones nanoparticuladas y macroparticuladas.
EP2988655B1 (en) 2013-04-26 2023-04-12 Genentech, Inc. Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE293808C (cg-RX-API-DMAC7.html)
DE159877C (cg-RX-API-DMAC7.html)
DE80967C (cg-RX-API-DMAC7.html)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
DK0752248T3 (da) * 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
PT725642E (pt) * 1993-10-27 2000-05-31 Upjohn Co Prostaglandina e 1 estabilizada
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
ATE315392T1 (de) * 1998-07-09 2006-02-15 Francis A Nardella Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR20040025880A (ko) * 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 수용해성이 개선된 의약 조성물
EP1350793A1 (en) * 2000-12-11 2003-10-08 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
EP1435877B1 (de) * 2001-10-15 2009-04-15 Hemoteq AG Beschichtung von stents zur verhinderung von restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
ATE389183T1 (de) 2002-03-22 2008-03-15 Univ Muenchen L Maximilians Zytokapazität-verfahren
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
MXPA04011111A (es) 2002-05-09 2005-07-14 Hemoteq Gmbh Productos medicos que comprenden un revestimiento hemocompatible, produccion y uso de los mismos.
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1594900A2 (en) * 2003-02-14 2005-11-16 Salmedix, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN102177140B (zh) * 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法

Also Published As

Publication number Publication date
KR20110110293A (ko) 2011-10-06
MX2011007557A (es) 2011-08-12
BRPI1004922A2 (pt) 2019-09-24
NZ594010A (en) 2013-08-30
ZA201105099B (en) 2012-03-28
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
CA2749101A1 (en) 2010-07-22
CN102281877A (zh) 2011-12-14
CN103554030A (zh) 2014-02-05
AU2016204902A1 (en) 2016-08-04
SG172810A1 (en) 2011-08-29
EP2387400A1 (en) 2011-11-23
IL213725A0 (en) 2011-07-31
US8076366B2 (en) 2011-12-13
CN102281877B (zh) 2014-07-23
WO2010083276A1 (en) 2010-07-22
JP2012515210A (ja) 2012-07-05
AU2010204765A1 (en) 2011-07-28
US20100210701A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
UA109109C2 (uk) Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
IN2012DN03182A (cg-RX-API-DMAC7.html)
PL2247582T3 (pl) Postać krystaliczna bezwodna dimetoksydocetakselu i sposoby jej wytwarzania
MX339805B (es) Compuestos organicos.
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
PH12012501164A1 (en) Imidazopyridine derivatives as jak inhibitors
UA99787C2 (en) Lactams as beta secretase inhibitors
IN2015DN01119A (cg-RX-API-DMAC7.html)
MX340714B (es) Inhibidores de hsp90.
MX2013010898A (es) Novedoso derivados de la pirimidina.
NZ590650A (en) Buprenorphine analogs
MX2012013274A (es) Novedosos derivados de la pirimidina.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
MX2011011109A (es) Formulaciones orales de bendamustina.
MX354691B (es) Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
IN2012DN03042A (cg-RX-API-DMAC7.html)
PH12017500089B1 (en) Aldosterone synthase inhibitors
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
MX343234B (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
IN2013DN02555A (cg-RX-API-DMAC7.html)
SI2003978T1 (sl) Alogenska celiäśna terapija za zdravljenje opurtunistiäśnih okuĺ˝b
WO2011125006A3 (en) Sultam compounds
PL2184072T3 (pl) Wytwarzanie preparatu jednorodnej szczepionki do leczenia raka